TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02614651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Find visual comfort threshold related to light intensity
Description: In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Find the size of the visual field
Description: For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effectiveness of brightness control
Description: During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performance of color correction
Description: During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vuzix Wrap 1200DX virtural reality glasses
Description: The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
Study: NCT03188627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells
Description: Transplantation of autologous bronchial basal cells
Study: NCT06250075

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-intervention for Clinical Outcomes -G5
Description: only observation of clinical outcomes in the postoperative period
Study: NCT04255186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency
Description: Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency
Description: Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: a simulated stimulation protocol so that the device does not emit current
Study: NCT03924245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given by mouth
Study: NCT04540211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab Matching Placebo
Description: Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Study: NCT00368082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbeta resistant LMP-specific CTLs
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2
Study: NCT04326959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium
Description: Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
Study: NCT03796832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flat Flexible Shoes
Description: Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stable Supportive Shoes
Description: Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
Study: NCT03924245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given by mouth
Study: NCT04122924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Description: The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
Study: NCT03545386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Stool from healthy donor administered via enema

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline with food coloring administered via enema
Study: NCT03796832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
Study: NCT00210132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT03169309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Entrainment Technology
Description: Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
Study: NCT03508375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: blood samples
Study: NCT03971071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab 70 mg
Description: Erenumab once every 4 weeks. Subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab 140 mg
Description: Erenumab once every 4 weeks. Subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once every 4 weeks. Subcutaneous injection.
Study: NCT00553969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol phosphate
Description: Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: tablets, 10mg once daily for 1 month, 20mg once daily for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol phosphate and lisinopril
Description: carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and placebo
Description: capsule once daily for 9 months; dosage unknown
Study: NCT01725607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with dexmedetomidine infusion
Description: general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with TEA
Description: general anesthesia combined with TEA (Group E)
Study: NCT02413177

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG-no RTNF
Description: All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG-RTNF
Description: All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
Study: NCT01276067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet
Study: NCT03024801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma
Description: The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: The patients with knee cartilage injury were randomized to the normal saline group.
Study: NCT05956873

Intervention type: DEVICE
Intervention: REVAR
Description: Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
Study: NCT03956381

Intervention type: DEVICE
Intervention: Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.
Description: The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.

Intervention type: DEVICE
Intervention: Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach
Description: The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
Study: NCT01932073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
Study: NCT02434367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk With Ease Arm A
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
Study: NCT02164773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%normal saline
Description: use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
Study: NCT00126607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00957112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo therapist-acupuncture with or without self-acupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo therapist-acupuncture with or without self-acupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo therapist-acupuncture with or without self-acupuncture

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: standard follow-up care
Description: Patients receive standard care

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: standard follow-up care
Description: Patients receive standard care
Study: NCT00614328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
Study: NCT03579576

Intervention type: DRUG
Intervention: sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.
Description: Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
Study: NCT04350606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06462700
Description: PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
Study: NCT02499978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat
Description: Fixed dose combination medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Fixed dose combination medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: single tablet medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: single tablet medication
Study: NCT01842815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755 nm alexandrite laser
Description: 755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755 nm alexandrite laser
Description: 755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
Study: NCT00292318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study
Description: Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
Study: NCT03150368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT03882463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with the stop insulin pump function
Description: Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology.
Study: NCT00928109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cognitive Behavioral Couples Therapy - weekly manualized couples therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Supportive Therapy
Description: Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
Study: NCT03853499

Intervention type: OTHER
Intervention: No intervention (observational study)
Description: No intervention (observational study)
Study: NCT01304147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of intranasal ketamine up to 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of saline intranasal
Study: NCT02229682

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mild-dose IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
Study: NCT00292318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Medical counseling and ano-sphinctal exercises.
Study: NCT03221907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1
Description: Pregabalin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLA5PR GLARS-NF1 placebo
Description: tablet manufactured to mimic GLA5PR GLARS-NF1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin placebo
Description: tablet manufactured to mimic pregabalin capsule